Related Experiment Video
Updated: Mar 24, 2026

07:20
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
15.4K
Summary
Researchers are improving adoptive T-cell therapy by genetically modifying specific, long-lasting T cells. This ensures a powerful cancer treatment that remains effective even at very low doses.
Area of Science:
- Immunology
- Oncology
- Cellular Therapy
Background:
- Adoptive T-cell therapy is a promising cancer treatment.
- Redirecting T-cell specificity toward tumors is an ongoing research area.
Discussion:
- Selecting persistent and proliferative T cells is key.
- Genetic manipulation of these specific T-cell subsets enhances therapeutic potency.
Key Insights:
- A refined method for T-cell selection and genetic modification has been developed.
- This approach yields a potent therapeutic product effective at minimal doses.
Outlook:
- Further optimization of T-cell selection criteria may enhance treatment efficacy.
- This strategy holds potential for improving outcomes in adoptive T-cell therapy for various cancers.
Related Concept Videos
Tumor Immunotherapy
2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
T Cell Activation and Clonal Selection
17.2K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
17.2K
Cell-mediated Immune Responses
86.0K
Overview
86.0K

